Cost-effectiveness of Clozapine Monitoring After the First 6 Months
- 1 October 1996
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 53 (10) , 954-958
- https://doi.org/10.1001/archpsyc.1996.01830100104013
Abstract
From JAMA Psychiatry — Cost-effectiveness of Clozapine Monitoring After the First 6 MonthsKeywords
This publication has 12 references indexed in Scilit:
- Reduction of suicidality during clozapine treatment of neuroleptic- resistant schizophrenia: impact on risk-benefit assessmentAmerican Journal of Psychiatry, 1995
- Cost effectiveness of clozapine in neuroleptic-resistant schizophreniaAmerican Journal of Psychiatry, 1993
- Clozapine-Induced Agranulocytosis -- Incidence and Risk Factors in the United StatesNew England Journal of Medicine, 1993
- Assessment of Costs and Benefits of Drug Therapy for Treatment-Resistant Schizophrenia in the United KingdomThe British Journal of Psychiatry, 1993
- Clozapine and the Mandatory Monitoring SystemNew England Journal of Medicine, 1991
- A Two-Year Clinical and Economic Follow-Up of Patients on ClozapinePsychiatric Services, 1990
- Comments by a Sandoz OfficialPsychiatric Services, 1990
- Cost-Effectiveness of Clozapine for Treatment-Resistant Schizophrenic PatientsPsychiatric Services, 1990
- Clozapine-induced agranulocytosis: A situation report up to August 1976European Journal of Clinical Pharmacology, 1977
- Agranulocytosis during treatment with clozapineEuropean Journal of Clinical Pharmacology, 1977